Developer docs
API playgroundTry for free, no card

Search company profiles

Instil Bio

Full company profile

uuid00008i6

Namestring
Instil Bio
Legal namestring
Instil Bio, Inc.
Websiteurl
instilbio.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Instil Bio, Inc. is a clinical-stage biotechnology company headquartered in Dallas, Texas (5949 Sherry Lane, Suite 820) and listed on NASDAQ under ticker TIL. Founded in 2020, the company was historically focused on developing cell therapies for solid tumor cures, operating through its wholly-owned subsidiary Axion Bio. The original pipeline consisted of drug candidates AXN-2510 and AXN-27M, which were licensed ex-China from ImmuneOnco Biopharmaceuticals in August 2024 under a License and Collaboration Agreement.

As of early 2026, Instil Bio has undergone a near-complete strategic reset. In January 2026, Axion Bio discontinued clinical development of AXN-2510 and terminated its agreement with ImmuneOnco, with all ex-China rights reverting to ImmuneOnco and a 45.81% single-day stock decline. The company closed the majority of its Manchester, UK operations in March 2026 and replaced its auditor with RSM US LLP in April 2026. The company currently has no active therapeutic products or candidates in disclosed development.

The business model is pre-revenue: there are no commercial products, no licensing royalties currently flowing in (the prior ImmuneOnco agreement has been terminated), and the company reported a net loss of $71.4 million for full year 2025 and a $0.62 per share net loss in Q1 2026. Instil Bio is explicitly pivoting toward external innovation, with management stating in May 2026 that it is actively evaluating potential acquisitions and in-licensing opportunities to build a new pipeline. The company maintains a cash position of approximately $74.7 million as of Q1 2026, which management expects to fund operations beyond 2027, providing a finite runway for executing transactions before a capital raise or strategic alternative becomes necessary.

Short descriptiontext

Instil Bio is a pre-revenue, clinical-stage biotechnology company that has discontinued its cell-therapy programs and is now pivoting toward external innovation, actively evaluating acquisitions and in-licensing opportunities to build a new pipeline using its $74.7M cash balance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy development, oncology therapeutics, clinical stage biopharma, solid tumor research, drug pipeline licensing
Industry3 codes
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy Biopharmaceuticals
Social media profiles2 records
Revenue model1 record
1Pre-Revenue / Development Stage
TypeLicensing Royalties
Description

Instil Bio is a clinical-stage biotechnology company with no commercial products generating revenue. The company reported a net loss of $71.4 million for full year 2025 and $0.62 per share loss in Q1 2026. The company is pivoting toward external innovation, evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Instil Bio is a clinical-stage biotechnology company that has historically developed cell therapies for solid tumors through its subsidiary Axion Bio, including drug candidates AXN-2510 and AXN-27M. After discontinuing all disclosed clinical programs in January 2026 and terminating its license with ImmuneOnco Biopharmaceuticals, the company is now pivoting to evaluate potential acquisitions and in-licensing opportunities to build a focused therapeutic pipeline. The company currently has no active clinical candidates under disclosed development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. Based on recent corporate disclosures, the company has discontinued all of its disclosed clinical programs through its subsidiary Axion Bio, including AXN-2510 and AXN-27M, following the termination of its license and collaboration agreement with ImmuneOnco Biopharmaceuticals in January 2026. The company is currently pivoting toward external innovation, actively evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline. Instil Bio maintains a cash position of approximately $74.7 million as of Q1 2026, expected to fund operations beyond 2027. No active therapeutic products or candidates are currently in disclosed development.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1ImmuneOnco Biopharmaceuticals
Strategic tierFormer CoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

License and Collaboration Agreement for drug candidates AXN-2510 and AXN-27M. The original agreement was signed in August 2024, granting Axion Bio rights to develop and commercialize these candidates outside of China. The agreement was terminated in January 2026, with all ex-China rights reverting to ImmuneOnco.

biospace.com
Strategic tierInternalTypeOthersAnnounced on2026-01-01
Description

Wholly owned subsidiary of Instil Bio that discontinued clinical development of AXN-2510 and terminated the license agreement with ImmuneOnco in January 2026. Effectively ended all of the company's disclosed programs.

Strategic tierMinorTypeOthers
Description

Appointed as new auditor in April 2026, replacing Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The SEC filing indicated no disagreements or adverse opinions from Deloitte.

Strategic tierMinorTypeOthers
Description

Former auditor replaced by RSM US LLP in April 2026. No disagreements or adverse opinions were reported from Deloitte.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Highly comparable to Instil Bio's prior solid tumor cell therapy focus; board director Gwendolyn Binder is former CTO of Adaptimmune.

TypeDirect peer
Description

Leading commercial-stage developer of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Most relevant direct competitor in the solid tumor cell therapy space where Instil previously operated.

TypeDirect peer
Description

Clinical-stage allogeneic CAR T cell therapy developer. Comparable as a public, clinical-stage cell therapy company pursuing off-the-shelf oncology cell therapy approaches.

TypeDirect peer
Description

Clinical-stage gene-edited allogeneic cell therapy company. Comparable in modality (engineered cell therapy), clinical stage, and oncology focus.

TypeEmerging player
Description

Clinical-stage cell therapy company focused on CAR T therapies. Board director Gwendolyn Binder is President of Science and Technology at Cabaletta, creating a direct professional linkage to Instil's board.

TypeEmerging player
Description

Clinical-stage T cell receptor therapy developer for solid tumors. Board director Neil Gibson serves on TCR2's board and CEO Bronson Crouch was an early investor, providing direct comparability.

TypeEmerging player
Description

Clinical-stage immunotherapy company developing fusion proteins for cancer and inflammatory diseases. Board director Neil Gibson sits on Shattuck's board; comparable in clinical-stage oncology focus.

8Chimeric Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company focused on solid tumors. Board director George Matcham previously served on Chimeric's board; comparable in solid tumor cell therapy focus.

TypeBroad incumbent
Description

Established commercial-stage RNAi therapeutics company. Strategic advisor John Maraganore was Alnylam's founding CEO for nearly two decades; comparable as a publicly-traded biotech with platform-based therapeutic approach.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing next-generation immunotherapies. CEO Bronson Crouch was a key early investor, providing a comparable case of a biotech Crouch backed through value-inflection stages.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Instil Bio

Cell Therapy Biopharmaceuticalsinstilbio.com

Instil Bio is a pre-revenue, clinical-stage biotechnology company that has discontinued its cell-therapy programs and is now pivoting toward external innovation, actively evaluating acquisitions and in-licensing opportunities to build a new pipeline using its $74.7M cash balance.

What Instil Bio does

Instil Bio, Inc. is a clinical-stage biotechnology company headquartered in Dallas, Texas (5949 Sherry Lane, Suite 820) and listed on NASDAQ under ticker TIL. Founded in 2020, the company was historically focused on developing cell therapies for solid tumor cures, operating through its wholly-owned subsidiary Axion Bio. The original pipeline consisted of drug candidates AXN-2510 and AXN-27M, which were licensed ex-China from ImmuneOnco Biopharmaceuticals in August 2024 under a License and Collaboration Agreement.

As of early 2026, Instil Bio has undergone a near-complete strategic reset. In January 2026, Axion Bio discontinued clinical development of AXN-2510 and terminated its agreement with ImmuneOnco, with all ex-China rights reverting to ImmuneOnco and a 45.81% single-day stock decline. The company closed the majority of its Manchester, UK operations in March 2026 and replaced its auditor with RSM US LLP in April 2026. The company currently has no active therapeutic products or candidates in disclosed development.

The business model is pre-revenue: there are no commercial products, no licensing royalties currently flowing in (the prior ImmuneOnco agreement has been terminated), and the company reported a net loss of $71.4 million for full year 2025 and a $0.62 per share net loss in Q1 2026. Instil Bio is explicitly pivoting toward external innovation, with management stating in May 2026 that it is actively evaluating potential acquisitions and in-licensing opportunities to build a new pipeline. The company maintains a cash position of approximately $74.7 million as of Q1 2026, which management expects to fund operations beyond 2027, providing a finite runway for executing transactions before a capital raise or strategic alternative becomes necessary.

Instil Bio firmographics

Firmographics
Name
Instil Bio
Legal name
Instil Bio, Inc.
Website
https://instilbio.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Instil Bio is a pre-revenue, clinical-stage biotechnology company that has discontinued its cell-therapy programs and is now pivoting toward external innovation, actively evaluating acquisitions and in-licensing opportunities to build a new pipeline using its $74.7M cash balance.
Ownership category
akta.pro rank

Where Instil Bio is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Instil Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-Revenue / Development Stage: Instil Bio is a clinical-stage biotechnology company with no commercial products generating revenue. The company reported a net loss of $71.4 million for full year 2025 and $0.62 per share loss in Q1 2026. The company is pivoting toward external innovation, evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline.

Marketing channels3 records

Instil Bio product offering

Product offering

Core offering

Instil Bio is a clinical-stage biotechnology company that has historically developed cell therapies for solid tumors through its subsidiary Axion Bio, including drug candidates AXN-2510 and AXN-27M. After discontinuing all disclosed clinical programs in January 2026 and terminating its license with ImmuneOnco Biopharmaceuticals, the company is now pivoting to evaluate potential acquisitions and in-licensing opportunities to build a focused therapeutic pipeline. The company currently has no active clinical candidates under disclosed development.

Product overview

Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. Based on recent corporate disclosures, the company has discontinued all of its disclosed clinical programs through its subsidiary Axion Bio, including AXN-2510 and AXN-27M, following the termination of its license and collaboration agreement with ImmuneOnco Biopharmaceuticals in January 2026. The company is currently pivoting toward external innovation, actively evaluating potential acquisitions and in-licensing opportunities to build a focused pipeline. Instil Bio maintains a cash position of approximately $74.7 million as of Q1 2026, expected to fund operations beyond 2027. No active therapeutic products or candidates are currently in disclosed development.

Differentiator

Problem solved

Functional benefit

Companies that use Instil Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Instil Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Instil Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered former core, internal and minor.

  • ImmuneOnco Biopharmaceuticalsformer coreStrategic or Co-development Partner · 1 January 2026License and Collaboration Agreement for drug candidates AXN-2510 and AXN-27M. The original agreement was signed in August 2024, granting Axion Bio rights to develop and commercialize these candidates outside of China. The agreement was terminated in January 2026, with all ex-China rights reverting to ImmuneOnco.
  • Axion BiointernalOthers · 1 January 2026Wholly owned subsidiary of Instil Bio that discontinued clinical development of AXN-2510 and terminated the license agreement with ImmuneOnco in January 2026. Effectively ended all of the company's disclosed programs.
  • RSM US LLPminorOthersAppointed as new auditor in April 2026, replacing Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The SEC filing indicated no disagreements or adverse opinions from Deloitte.
  • Deloitte & Touche LLPminorOthersFormer auditor replaced by RSM US LLP in April 2026. No disagreements or adverse opinions were reported from Deloitte.

Scale indicators7 records

Recent moves5 records

Expansion highlights3 records

Instil Bio competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Highly comparable to Instil Bio's prior solid tumor cell therapy focus; board director Gwendolyn Binder is former CTO of Adaptimmune.
  • Iovance Biotherapeutics: Leading commercial-stage developer of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Most relevant direct competitor in the solid tumor cell therapy space where Instil previously operated.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR T cell therapy developer. Comparable as a public, clinical-stage cell therapy company pursuing off-the-shelf oncology cell therapy approaches.
  • Cellectis: Clinical-stage gene-edited allogeneic cell therapy company. Comparable in modality (engineered cell therapy), clinical stage, and oncology focus.

Emerging players

  • Cabaletta Bio: Clinical-stage cell therapy company focused on CAR T therapies. Board director Gwendolyn Binder is President of Science and Technology at Cabaletta, creating a direct professional linkage to Instil's board.
  • TCR2 Therapeutics: Clinical-stage T cell receptor therapy developer for solid tumors. Board director Neil Gibson serves on TCR2's board and CEO Bronson Crouch was an early investor, providing direct comparability.
  • Shattuck Labs: Clinical-stage immunotherapy company developing fusion proteins for cancer and inflammatory diseases. Board director Neil Gibson sits on Shattuck's board; comparable in clinical-stage oncology focus.
  • Chimeric Therapeutics: Clinical-stage cell therapy company focused on solid tumors. Board director George Matcham previously served on Chimeric's board; comparable in solid tumor cell therapy focus.
  • iTeos Therapeutics: Clinical-stage immuno-oncology company developing next-generation immunotherapies. CEO Bronson Crouch was a key early investor, providing a comparable case of a biotech Crouch backed through value-inflection stages.

Broad incumbents

  • Alnylam Pharmaceuticals: Established commercial-stage RNAi therapeutics company. Strategic advisor John Maraganore was Alnylam's founding CEO for nearly two decades; comparable as a publicly-traded biotech with platform-based therapeutic approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Customer concentration

Instil Bio social profiles

Digital presence

Instil Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Instil Bio leadership team

Management profile

Number of profiles

Profiles11 records

Instil Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Instil Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Instil Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instil Bio

What does Instil Bio do?

Instil Bio is a clinical-stage biotechnology company that has historically developed cell therapies for solid tumors through its subsidiary Axion Bio, including drug candidates AXN-2510 and AXN-27M. After discontinuing all disclosed clinical programs in January 2026 and terminating its license with ImmuneOnco Biopharmaceuticals, the company is now pivoting to evaluate potential acquisitions and in-licensing opportunities to build a focused therapeutic pipeline. The company currently has no active clinical candidates under disclosed development.

Is Instil Bio a public or private company?

Instil Bio is a public company. It is classified as public and is currently operating.

When was Instil Bio founded?

Instil Bio was founded in 2020. It employs 11 to 50 people.

Where is Instil Bio based?

Instil Bio is headquartered in Dallas, United States, in the North America region.

How does Instil Bio make money?

One revenue line is on record: pre-Revenue / Development Stage.

Who are Instil Bio's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Iovance Biotherapeutics, Allogene Therapeutics and Cellectis. Emerging players are Cabaletta Bio, TCR2 Therapeutics, Shattuck Labs, Chimeric Therapeutics and iTeos Therapeutics. Alnylam Pharmaceuticals is listed as a broad incumbent.

Does Instil Bio have an API?

No public API is recorded for Instil Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerInstil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Instil Bio reported a Q3 net loss of $4.23 million, down from $13.59 million a year ago, and a nine-month net loss of $13.02 million, down from $63.5 million. Basic and diluted loss per share from continuing operations were $0.62 and $1.92, respectively, compared to $2.01 and $9.58 a year ago.Quiver QuantitativeInstil Bio Reports $4.2 Million Third-Quarter Net Loss | TIL Stock NewsInstil Bio reported a third-quarter 2026 net loss of $4.2 million, down from $13.6 million a year earlier. The company held $67.1 million in cash and investments as of September 30, 2026, and expects this to fund its operating plan through 2027.The future of tradingInstil Bio, Inc. <til.oq> expected to post a loss of 17 cents a share - Earnings PreviewInstil Bio, Inc. is expected to report a loss of 17 cents per share for the period ending September 30, 2026. The one available analyst rating is "hold," and the median 12-month price target is $7.00, about 2.5% above the last closing price of $6.83.BioSpaceInstil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateInstil Bio reported Q2 2026 results with a cash position of $69.9 million as of June 30, 2026, and a net loss of $8.5 million for the six months. The company expects its cash to fund operations beyond 2027 and is evaluating potential acquisitions and in-licensing opportunities.Quiver QuantitativeInstil Bio Reports $4.3 Million Second-Quarter 2026 Net Loss | TIL Stock NewsInstil Bio reported a net loss of $4.3 million, or $0.63 per share, for the second quarter ended June 30, 2026, a significant improvement from the $21.4 million loss in the prior-year period. The company holds $69.9 million in cash and marketable securities, which management expects will fund operations beyond 2027. Additionally, Instil stated it is actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates.YahooInstil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateInstil Bio reported its second quarter 2026 financial results, revealing a cash position of approximately $69.9 million which is expected to fund operations beyond 2027. The company recorded significantly reduced research and development expenses compared to the same period in 2025, reflecting a shift toward evaluating potential acquisitions and in-licensing opportunities.Stock TitanInstil Bio Q2 Earnings: $0.63 Loss, $69.9M CashInstil Bio reported a net loss of $0.63 per share for the second quarter of 2026, marking a significant improvement from the $3.24 loss in the same period last year. The company ended the quarter with approximately $69.9 million in cash and marketable securities, which management expects will fund its operating plan beyond 2027.Stock TitanInstil Bio Q1 2026 loss $0.62, $74.7M cash runwayInstil Bio reported first quarter 2026 financial results with a net loss of $0.62 per share, significantly improved from $4.32 per share in the prior year period. The company ended Q1 2026 with approximately $74.7 million in cash, cash equivalents, restricted cash and marketable securities, which it expects to fund current operations beyond 2027. Instil stated it is actively evaluating potential acquisitions and in-licensing opportunities as part of its strategic development.GlobeNewswireInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInstil Bio reported first quarter 2026 financial results, with cash, cash equivalents, restricted cash and marketable securities of approximately $74.7 million as of March 31, 2026. Research and development expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62 from $4.32 in the prior year period. The company announced it is actively evaluating potential acquisitions and in-licensing opportunities, with management stating the strong balance sheet positions it to build a focused pipeline.Investing.comInstil Bio appoints RSM US as new auditor, replacing Deloitte & Touche By Investing.comInstil Bio has appointed RSM US LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Deloitte & Touche LLP, which had served for fiscal years 2024 and 2025. The company also discontinued clinical programs through its subsidiary Axion Bio, mutually terminating its License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals for drug candidates AXN-2510 and AXN-27M, with all rights reverting to ImmuneOnco. Following these developments, Baird downgraded Instil Bio's stock from Outperform to Neutral, while the company confirmed Axion Bio retains a limited license to conclude ongoing clinical activities.